Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Inotiv
NOTV
NOTV
Inotiv
Debt And Shifting Regulations Will Strain Performance But Prompt Recovery
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 3 Analysts
Published
14 Aug 25
Updated
14 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$2.50
24.4% undervalued
intrinsic discount
14 Aug
US$1.89
Loading
1Y
20.4%
7D
3.3%
Author's Valuation
US$2.5
24.4% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$2.5
24.4% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-340m
1b
2014
2017
2020
2023
2025
2026
2028
Revenue US$1.0b
Earnings US$148.7m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
5.39%
Life Sciences revenue growth rate
0.33%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
12.32%
Calculation
US$148.74m
Earnings '28
x
1.80x
PE Ratio '28
=
US$267.38m
Market Cap '28
US$267.38m
Market Cap '28
/
75.48m
No. shares '28
=
US$3.54
Share Price '28
US$3.54
Share Price '28
Discounted to 2025 @ 12.32% p.a.
=
US$2.50
Fair Value '25
